Tag Archives: Martin Auster

BioMarin Pharmaceutical (BMRN) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of $128.00. The company’s shares closed last Wednesday at $120.23. According to TipRanks.com, Auster is a 5-star analyst

Credit Suisse Remains a Buy on MyoKardia (MYOK)

In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on MyoKardia (MYOK – Research Report), with a price target of $136.00. The company’s shares closed last Wednesday at $101.37. According to TipRanks.com, Auster is a

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Incyte (NASDAQ: INCY) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Incyte (INCY – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report). Sarepta Therapeutics (SRPT) Credit Suisse

Credit Suisse Thinks uniQure’s Stock is Going to Recover

In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on uniQure (QURE – Research Report), with a price target of $76.00. The company’s shares closed last Friday at $41.33, close to its 52-week low of

Ultragenyx Pharmaceutical (RARE) Receives a Hold from Credit Suisse

In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $64.00. The company’s shares closed last Friday at $77.98. According to TipRanks.com, Auster is

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Premier (NASDAQ: PINC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report) and Premier (PINC – Research Report). BioMarin Pharmaceutical (BMRN) In a report released yesterday, Martin Auster from Credit Suisse